Boston-based nonprofit MassRobotics is seeking participants for the sixth cohort of its Healthcare Robotics Startup Catalyst Program, which supports robotics startups in the healthcare and life sciences sectors. Applications are due by December 31, 2026, and the program runs for four months, from February to June 2027. At the end, companies are expected to showcase their progress at the Robotics Summit & Expo in Boston.
From Prototype to Hospital Floor: A Four-Month Program Offering Hands-On Support
A medical robot isn’t finished just because it moves. Does it fit the flow of a clinical setting? Can doctors and nurses use it with confidence? How should it be explained to regulators? Obstacles beyond the technology itself emerge one after another from the earliest stages of development. MassRobotics’ program offers startups facing those challenges on their own the expertise and networks of people who have been through them.
The program is non-equity, meaning it takes no ownership stake. It is open to companies developing robotics or automation technologies for healthcare and biotech. During the program, participants work toward concrete goals such as building proof-of-concept prototypes, designing pilot deployments, planning for regulatory requirements and integrating systems. The program connects them with senior mentors from corporate partners as well as practicing clinicians and leading organizations in healthcare.
From the Lab to the Operating Room
Eligible areas are broad, including laboratory and pharmaceutical automation; diagnostic and imaging workflows; in-hospital logistics; operating-room automation; rehabilitation and assistive devices; and robots for surgery and interventional procedures. Foundational technologies such as sensing, precision control, edge AI and medical-device cybersecurity are also in scope.
The program is open to companies from outside the United States, and startups at funding stages from seed through Series C are welcome to apply. Applicants will be assessed on technological maturity, clinical relevance, their ability to meet near-term milestones, fit with the program and fit with mentors. Teams that can reach proof of concept during the four-month program are especially welcome.
Intel Brings an Edge AI Perspective to the Program
Intel has joined the steering committee for the sixth cohort. It joins founding participants Festo, Novanta and Mitsubishi Electric’s U.S. subsidiary. Intel’s Health and Life Sciences division says it will contribute expertise in edge AI and on-device computing for robots that support surgery and procedures, as well as operating-room automation.
Edge AI refers to processing AI workloads close to the device, without relying on the cloud. In situations such as surgery, where even a moment’s delay is unacceptable, the ability to make decisions on the spot without going through a network is a design advantage. According to program materials, participants in this cohort are showing growing interest in the field. Having a mentor with chip expertise could make it easier for companies to get advice on designs that consider not only performance but also real-world operations.
Past Participants Show the Program’s Reach
Since the program launched in 2021, 35 companies have participated. The teams, at stages ranging from pre-seed to Series A, are based in cities around the world, including Boston, Toronto, Paris, Barcelona and Sydney. MassRobotics says alumni have gone public, advanced multiple proof-of-concept projects toward deployment, and reported raising more than $180 million in total.
These figures, of course, reflect results disclosed by participating companies and cannot be attributed to the program’s support alone. Still, the fact that several companies have advanced from early prototypes to stages closer to market suggests that the four-month program is serving as a launchpad for their next steps in business.
Whelix CEO Bingda Li, whose company develops robots for automating cell culture, praised the opportunity to consult directly with people who had faced the same challenges. Johannes Linzbach of Festo also pointed to the growth of companies such as Tenomix, reflecting on his three years of supporting the program as a founding member.
From Selection to Showcase
Evaluation and interviews will take place from January 1 to 20, 2027, after the application deadline. The participating companies are scheduled to be announced on January 29. After the program runs from February to June, they will present their progress at the Robotics Summit & Expo showcase.
The program begins with onboarding and goal setting, followed by working sessions with mentors every other week. Workshops tailored to participants’ needs will also cover regulatory strategy, cybersecurity and software bills of materials (SBOMs), clinical workflows and pilot design.
A medical robot does not become a product through technical maturity alone. Success depends on how well companies advance their work in clinical settings, regulation and business at the same time. Which challenges the sixth cohort’s companies tackle first will be worth watching when they showcase their work in Boston in June 2027.
Comments